BiotechTube
MV BioTherapeutics

MV BioTherapeutics

Geneva, Switzerland· Est.
mv-bio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MV BioTherapeutics is a private, preclinical-stage biotech leveraging novel microbiome-based platforms to develop therapeutics for enteric and systemic diseases. Its ApyraMed platform uses apyrase enzymes to improve intestinal fitness and immune competence, targeting inflammatory bowel disease and cancer. The ApyraVax platform is designed to elicit potent mucosal IgA responses against pathogens, positioning the company in the growing fields of microbiome therapeutics and mucosal vaccines.

GastroenterologyOncologyInfectious Diseases

Technology Platform

Two platforms centered on the enzyme apyrase: 1) ApyraMed uses apyrase (as recombinant protein or via live biotherapeutics) to degrade pro-inflammatory extracellular ATP, improving intestinal fitness and immune competence. 2) ApyraVax uses apyrase as a mucosal adjuvant to powerfully amplify secretory IgA (sIgA) responses against co-administered antigens for vaccination.

Opportunities

The company targets large, growing markets in IBD, cancer immunotherapy, and mucosal vaccines with a novel, platform-based approach.
Success in clinical proof-of-concept could lead to valuable partnerships or acquisition, particularly given the strategic interest in microbiome modulation and mucosal immunity.

Risk Factors

The entire pipeline is preclinical, carrying high biological and development risk.
As a private, pre-revenue company, it faces significant financing and execution risk to advance into clinical trials.
It also operates in competitive therapeutic areas with many established and emerging players.

Competitive Landscape

MV BioTherapeutics competes in the crowded and competitive microbiome therapeutics space, facing companies like Seres Therapeutics, Vedanta Biosciences, and numerous startups. In mucosal vaccines, it competes with entities developing novel adjuvants and delivery systems. Its differentiation lies in its specific focus on apyrase-mediated modulation of extracellular nucleotides, a niche mechanism within these broader fields.

More companies in Switzerland →